Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma”

59 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 59 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05715931
What this trial is testing

Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Who this might be right for
Adenocarcinoma of the StomachAdenocarcinoma of Esophagogastric JunctionHER2-positive Gastric Cancer
Yu jiren 30
Testing effectiveness (Phase 2)UnknownNCT05111444
What this trial is testing

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric NeoplasmsGastroesophageal Junction Adenocarcinoma
Fudan University 65
Large-scale testing (Phase 3)Not Yet RecruitingNCT07818070
What this trial is testing

A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma

Who this might be right for
Gastric CancerEsophagogastric Junction CancerEsophageal Adenocarcinoma
Ono Pharmaceutical Co., Ltd. 600
Not applicableStudy completedNCT05892926
What this trial is testing

HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia

Who this might be right for
Adenocarcinoma
AstraZeneca 204
Testing effectiveness (Phase 2)Looking for participantsNCT07025889
What this trial is testing

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

Who this might be right for
Gastric Cancer
Ruijin Hospital 55
Testing effectiveness (Phase 2)Study completedNCT01472029
What this trial is testing

Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the Stomach
AIO-Studien-gGmbH 53
Post-approval studies (Phase 4)Not Yet RecruitingNCT07829757
What this trial is testing

Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Large-scale testing (Phase 3)Active Not RecruitingNCT04704934
What this trial is testing

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Who this might be right for
Gastric Cancer, AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Daiichi Sankyo 490
Large-scale testing (Phase 3)Active Not RecruitingNCT03504397
What this trial is testing

Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Early research (Phase 1)Not Yet RecruitingNCT07581574
What this trial is testing

Neoadjuvant SHR-A1811 and SHR-A1701 for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University 12
Large-scale testing (Phase 3)Active Not RecruitingNCT03653507
What this trial is testing

Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07685704
What this trial is testing

Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
Zhifeng Zhao, PhD 46
Testing effectiveness (Phase 2)Looking for participantsNCT07327229
What this trial is testing

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited 132
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07490990
What this trial is testing

Disitamab Vedotin Combined With Sintilimab and Multimodal Radiotherapy for HER2-Positive Advanced Gastric Cancer After Second-Line Treatment Failure: A Prospective, Single-Arm Phase II Clinical Trial

Who this might be right for
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
West China Hospital 30
Testing effectiveness (Phase 2)Study completedNCT01364493
What this trial is testing

Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
Peking University 51
Large-scale testing (Phase 3)Looking for participantsNCT07431281
What this trial is testing

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaEsophageal Cancer
AstraZeneca 2,130
Large-scale testing (Phase 3)Ended earlyNCT01641939
What this trial is testing

Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 415
Testing effectiveness (Phase 2)Active Not RecruitingNCT06423885
What this trial is testing

BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd. 64
Large-scale testing (Phase 3)Looking for participantsNCT07673887
What this trial is testing

ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc. 570
Not applicableLooking for participantsNCT07427992
What this trial is testing

Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
European Institute of Oncology 70
Next Page
50
565
507